Format

Send to

Choose Destination
J Neuroradiol. 2010 May;37(2):89-97. doi: 10.1016/j.neurad.2009.04.005. Epub 2009 Jun 30.

Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: preliminary results in clinical practice.

Author information

1
Department of Medical Imaging, MRI Unit, cliniques universitaires Saint-Luc, université catholique de Louvain, 10, avenue Hippocrate, 1200 Brussels, Belgium. vinciane.dandois@advalvas.be

Abstract

PURPOSE:

Our aim was to compare perfusion magnetic resonance imaging (MRI) and positron emission tomography (PET) using carbon-11 labelled methionine (MET) in gliomas and their value in differentiating tumour recurrence from necrosis.

MATERIALS AND METHODS:

We retrospectively reviewed 28 patients with a high-grade glioma. A total of 33MR perfusions and MET-PET were ultimately analysable for comparison between the relative cerebral blood volume (rCBV) and MET-PET examinations. Intra- and interobserver reproducibility was assessed and diagnostic value of rCBV compared to MET-PET and histology was assessed by the area under the receiver operating characteristic (ROC) curve.

RESULTS:

ROC curve analysis showed that rCBV had at least equal performances in differentiating tumour recurrence and necrosis than MET-PET. Cut-off value of rCBV for differentiating tumour from necrosis was 182% with a sensitivity of 81.5% and a specificity of 100%.

CONCLUSION:

In clinical practice, perfusion MRI could replace MET-PET for differentiating necrosis from tumour recurrence.

PMID:
19570578
DOI:
10.1016/j.neurad.2009.04.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center